← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

Nano-X Imaging Ltd. (NNOX) 10-Year Financial Performance & Capital Metrics

NNOX • • Industrial / General
HealthcareMedical DevicesDiagnostic & Imaging EquipmentMedical Imaging Systems
AboutNano-X Imaging Ltd. develops a commercial-grade tomographic imaging device with a digital X-ray source. The company provides teleradiology services and develops artificial intelligence applications to be used in real-world medical imaging applications. Its X-ray source is based on a digital micro-electro-mechanical systems semiconductor cathode. The company develops a prototype of the Nanox.ARC, a medical imaging system incorporating its digital X-ray source; and Nanox.CLOUD, a companion cloud-based software that would allow for the delivery of medical screening as a service. It also offers Nanox.MARKETPLACE, which connects imaging facilities with radiologists and enables radiologists to provide, as well as customers to obtain remote interpretations of imaging data; artificial intelligence (AI)-based software imaging solutions to hospitals, health maintenance organizations, integrated delivery networks, pharmaceutical companies, and insurers that are designed to identify or predict undiagnosed or underdiagnosed medical conditions through the mining of data included in images of existing computed tomography scans for osteoporosis and cardiovascular disease; Teleradiology Services, which provide imaging interpretation services for radiology practices, hospitals, medical clinics, diagnostic imaging centers, urgent care facilities; and multi-specialty physician groups, contracts, and radiology readings. The company was founded in 2011 and is headquartered in Neve Ilan, Israel.Show more
  • Revenue $11M +13.9%
  • EBITDA -$45M +11.4%
  • Net Income -$54M +11.9%
  • EPS (Diluted) -0.91 +15.7%
  • Gross Margin -94.03% -41.3%
  • EBITDA Margin -398.95% +22.2%
  • Operating Margin -502.93% +20.4%
  • Net Margin -474.31% +22.7%
  • ROE -27.83% +3.8%
  • ROIC -27.93% -0.7%
  • Debt/Equity 0.04 -8.3%
  • Interest Coverage -
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Company is almost debt free
  • ✓Trading at only 1.0x book value

✗Weaknesses

  • ✗Negative free cash flow
  • ✗Weak momentum: RS Rating 14 (bottom 14%)
  • ✗Trading more than 30% below 52-week high
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y-
3Y105.3%
TTM15.19%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM-12.08%

EPS CAGR

10Y-
5Y-
3Y-
TTM-3.53%

ROCE

10Y Avg-31.81%
5Y Avg-31.81%
3Y Avg-32.33%
Latest-28.43%

Peer Comparison

Medical Imaging Systems
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
IRMDIRadimed Corporation1.3B102.5768.3811.71%26.31%21.54%1.35%0.00
BRKRBruker Corporation7.52B49.4665.0813.56%-0.61%-0.84%1.81%1.24
STESTERIS plc26.33B268.2643.276.24%12.07%9.8%2.95%0.33
FONRFONAR Corporation114.98M18.6415.151.43%7.08%4.62%6.48%0.24
HYPRHyperfine, Inc.100.18M1.22-2.1816.84%-378.17%-149.05%0.01
PACBPacific Biosciences of California, Inc.709.48M2.35-2.20-23.19%-325.8%-13.95%1.33
IRIXIRIDEX Corporation23.21M1.35-2.50-6.17%-10.04%-108.67%2.21
MASS908 Devices Inc.199.79M5.52-2.6018.72%-7.17%-3.03%0.06

Profit & Loss

Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Sales/Revenue+0001.3M8.58M9.9M11.28M
Revenue Growth %----5.58%0.15%0.14%
Cost of Goods Sold+35K53K208K2.82M15.46M16.5M21.89M
COGS % of Revenue---2.16%1.8%1.67%1.94%
Gross Profit+-35K-53K-208K-1.51M-6.88M-6.59M-10.61M
Gross Margin %----1.16%-0.8%-0.67%-0.94%
Gross Profit Growth %--0.51%-2.92%-6.27%-3.55%0.04%-0.61%
Operating Expenses+1.9M22.57M43.92M60.05M72.33M56M46.14M
OpEx % of Revenue---46.05%8.43%5.65%4.09%
Selling, General & Admin1.23M19.85M34.71M41.74M45.63M28.39M25.75M
SG&A % of Revenue---32.01%5.32%2.87%2.28%
Research & Development672K2.72M9.21M17.12M26.51M26.05M20.18M
R&D % of Revenue---13.13%3.09%2.63%1.79%
Other Operating Expenses0001.18M191K1.55M206K
Operating Income+-1.9M-22.57M-43.92M-61.56M-109.71M-62.59M-56.75M
Operating Margin %----47.21%-12.79%-6.32%-5.03%
Operating Income Growth %--10.85%-0.95%-0.4%-0.78%0.43%0.09%
EBITDA+-1.87M-22.52M-43.72M-59.27M-98.2M-50.78M-45.01M
EBITDA Margin %----45.45%-11.45%-5.13%-3.99%
EBITDA Growth %--11.05%-0.94%-0.36%-0.66%0.48%0.11%
D&A (Non-Cash Add-back)35K53K208K2.29M11.51M11.81M11.73M
EBIT-1.9M-22.57M-43.81M-61.56M-87.21M-59.66M-56.75M
Net Interest Income+08K108K-288K789K1.65M2.87M
Interest Income08K108K0789K1.65M2.87M
Interest Expense5K00288K000
Other Income/Expense-5K8K108K-288K-14.67M1.47M2.87M
Pretax Income+-1.91M-22.56M-43.81M-61.85M-108.92M-61.12M-53.87M
Pretax Margin %----47.43%-12.7%-6.17%-4.77%
Income Tax+5K00-48K-3.68M-339K-358K
Effective Tax Rate %1%1%0.99%1%0.97%0.99%0.99%
Net Income+-1.91M-22.55M-43.5M-61.8M-105.24M-60.78M-53.52M
Net Margin %----47.39%-12.27%-6.14%-4.74%
Net Income Growth %--10.82%-0.93%-0.42%-0.7%0.42%0.12%
Net Income (Continuing)-1.91M-22.56M-43.81M-61.8M-113.24M-60.78M-53.52M
Discontinued Operations0000000
Minority Interest0000000
EPS (Diluted)+-0.06-0.49-1.22-1.28-2.01-1.08-0.91
EPS Growth %--7.77%-1.49%-0.05%-0.57%0.46%0.16%
EPS (Basic)-0.06-0.49-1.22-1.28-2.01-1.08-0.91
Diluted Shares Outstanding34.17M45.72M35.65M48.22M52.23M56.37M58.62M
Basic Shares Outstanding34.17M45.72M35.65M48.22M52.23M56.37M58.62M
Dividend Payout Ratio-------

Balance Sheet

Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Total Current Assets+1.7M9.64M219.79M94.86M82.46M88.64M78.68M
Cash & Short-Term Investments5K8.07M213.47M88.71M77.62M82.38M73.21M
Cash Only5K8.07M213.47M66.64M38.46M56.38M39.3M
Short-Term Investments00022.07M39.16M26.01M33.9M
Accounts Receivable0001.05M977K1.48M1.8M
Days Sales Outstanding---294.1841.5754.6958.39
Inventory0003.13M2.41M2.36M1.49M
Days Inventory Outstanding---405.575752.1324.89
Other Current Assets006.33M1.97M1.45M1.14M1.35M
Total Non-Current Assets+156K2.23M16.36M268.31M171.47M130.01M131.32M
Property, Plant & Equipment156K754K15.38M39.16M44.7M46.92M49.2M
Fixed Asset Turnover---0.03x0.19x0.21x0.23x
Goodwill00058.3M7.42M00
Intangible Assets000101.83M91.22M80.61M70M
Long-Term Investments0145K316K67.84M25.2M327K337K
Other Non-Current Assets01.34M661K1.18M2.93M2.16M11.79M
Total Assets+1.85M11.87M236.15M363.17M253.93M218.65M210M
Asset Turnover---0.00x0.03x0.05x0.05x
Asset Growth %-5.4%18.89%0.54%-0.3%-0.14%-0.04%
Total Current Liabilities+8.24M20.26M4.48M52.75M17.07M15.52M13.97M
Accounts Payable82K475K435K3.13M3.62M3.3M2.21M
Days Payables Outstanding855.143.27K763.34406.2285.4573.0836.83
Short-Term Debt00519K145K740K3.49M3.06M
Deferred Revenue (Current)01000K0247K182K543K140K
Other Current Liabilities001.08M44.73M7.55M3.41M3.85M
Current Ratio0.21x0.48x49.06x1.80x4.83x5.71x5.63x
Quick Ratio0.21x0.48x49.06x1.74x4.69x5.56x5.52x
Cash Conversion Cycle---293.5413.1233.7346.45
Total Non-Current Liabilities+82K386K923K18.27M12.18M7.61M6.91M
Long-Term Debt0003.8M3.48M00
Capital Lease Obligations0386K923K950K398K4.04M3.64M
Deferred Tax Liabilities0007.06M3.33M2.95M2.58M
Other Non-Current Liabilities0006.05M4.57M612K695K
Total Liabilities8.24M20.65M5.4M71.02M29.25M23.13M20.88M
Total Debt+0526K1.44M5.77M4.62M8.4M7.45M
Net Debt-5K-7.55M-212.03M-60.87M-33.84M-47.98M-31.86M
Debt / Equity--0.01x0.02x0.02x0.04x0.04x
Debt / EBITDA-------
Net Debt / EBITDA-------
Interest Coverage-380.80x---213.74x---
Total Equity+-6.38M-8.78M230.75M292.15M224.68M195.51M189.12M
Equity Growth %--0.38%27.29%0.27%-0.23%-0.13%-0.03%
Book Value per Share-0.19-0.196.476.064.303.473.23
Total Shareholders' Equity-6.38M-8.78M230.75M292.15M224.68M195.51M189.12M
Common Stock58K75K131K149K158K165K181K
Retained Earnings-18.04M-40.6M-84.42M-146.21M-251.46M-320.23M-373.75M
Treasury Stock0000000
Accumulated OCI-83K00-607K-1.97M-305K-1K
Minority Interest0000000

Cash Flow

Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+-3.67M-5.52M-21.49M-38.07M-43.38M-44.78M-36.6M
Operating CF Margin %----29.2%-5.06%-4.52%-3.24%
Operating CF Growth %--0.5%-2.89%-0.77%-0.14%-0.03%0.18%
Net Income-1.91M-22.56M-43.81M-61.8M-105.24M-60.78M-53.52M
Depreciation & Amortization35K53K208K2.29M11.51M11.81M11.73M
Stock-Based Compensation115K16.25M24.78M18.81M18.62M6.84M7.26M
Deferred Taxes0-16.35M-25.3M-116K-3.73M-377K-377K
Other Non-Cash Items185K16.35M25.3M-2K52.4M5.21M-572K
Working Capital Changes-1.91M741K-2.66M2.75M-16.95M-7.48M-1.13M
Change in Receivables000-40K74K-507K-321K
Change in Inventory000864K00-277K
Change in Payables-134K393K-103K1.72M469K-153K-1.32M
Cash from Investing+-73K-125K-13.94M-116.32M14.61M35.43M-20.05M
Capital Expenditures-73K-125K-13.94M-23.16M-7.17M-3.3M-2.77M
CapEx % of Revenue---17.76%0.84%0.33%0.25%
Acquisitions-------
Investments-------
Other Investing000-90.3M-1.01M-373K46K
Cash from Financing+3.68M13.86M240.99M7.38M804K27.25M39.5M
Debt Issued (Net)-------
Equity Issued (Net)-------
Dividends Paid0000000
Share Repurchases-------
Other Financing0-177K630K3.58M804K113K1.67M
Net Change in Cash-------
Free Cash Flow+-3.74M-5.65M-35.42M-61.23M-50.56M-48.08M-39.37M
FCF Margin %----46.95%-5.89%-4.85%-3.49%
FCF Growth %--0.51%-5.27%-0.73%0.17%0.05%0.18%
FCF per Share-0.11-0.12-0.99-1.27-0.97-0.85-0.67
FCF Conversion (FCF/Net Income)1.92x0.24x0.49x0.62x0.41x0.74x0.68x
Interest Paid00013K90K149K140K
Taxes Paid008K7K147K3K53K

Key Ratios

Metric2018201920202021202220232024
Return on Equity (ROE)---39.19%-23.64%-40.73%-28.93%-27.83%
Return on Invested Capital (ROIC)---2749.77%-36.94%-38.99%-27.75%-27.93%
Gross Margin----115.95%-80.21%-66.55%-94.03%
Net Margin----4739.11%-1226.89%-613.59%-474.31%
Debt / Equity--0.01x0.02x0.02x0.04x0.04x
Interest Coverage-380.80x---213.74x---
FCF Conversion1.92x0.24x0.49x0.62x0.41x0.74x0.68x
Revenue Growth----557.82%15.47%13.91%

Frequently Asked Questions

Growth & Financials

Nano-X Imaging Ltd. (NNOX) reported $12.3M in revenue for fiscal year 2024.

Nano-X Imaging Ltd. (NNOX) grew revenue by 13.9% over the past year. This is steady growth.

Nano-X Imaging Ltd. (NNOX) reported a net loss of $55.7M for fiscal year 2024.

Dividend & Returns

Nano-X Imaging Ltd. (NNOX) has a return on equity (ROE) of -27.8%. Negative ROE indicates the company is unprofitable.

Nano-X Imaging Ltd. (NNOX) had negative free cash flow of $46.7M in fiscal year 2024, likely due to heavy capital investments.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.